SMITHKLINE BEECHAM PAXIL U.S. SALES ARE $88 MIL. IN FIRST QUARTER; McKESSON DRUG REPORTS 9% GROWTH TO $9.7 BIL. IN DISTRIBUTION REVENUES WITHOUT PRICE INFLATION
Executive Summary
SmithKline Beecham's serotonin reuptake inhibitor antidepressant Paxil posted sales of $88 mil. ( (British Pound)59 mil.) in the U.S. in the first quarter, the company reported April 21.